Pulmonary hypertension complicating heart failure with preserved ejection fraction represents one of cardiology's most treatment-resistant intersections — no approved targeted therapy exists for this specific combination, making any mechanistic breakthrough clinically consequential. New findings published in Circulation identify a previously unappreciated molecular gatekeeper that, when lost, cascades into vascular remodeling and pressure elevation through a metabolic route few would have anticipated.
The protein GPRASP1 — historically classified as a G protein-coupled receptor sorting molecule — turns out to govern a critical metabolic checkpoint in pulmonary endothelial cells. When GPRASP1 expression is reduced, as observed in mouse models of PH-HFpEF, the enzyme asparagine synthetase (ASNS) becomes abnormally stabilized. This stabilization diverts aspartate away from oxaloacetate production within the tricarboxylic acid cycle and toward asparagine synthesis instead. The downstream consequences are striking: ATP depletion, reactive oxygen species accumulation, uncoupling of endothelial nitric oxide synthase, and ultimately a collapse in nitric oxide bioavailability. Mice with endothelial-specific Gprasp1 deletion recapitulated hallmark PH-HFpEF features — elevated pulmonary pressures, pulmonary vascular remodeling, diastolic dysfunction, and dysregulated glucose and lipid handling — establishing causality rather than mere association.
What makes this finding particularly noteworthy is the discovery that GPRASP1 acts as a non-canonical ASNS regulator, a function entirely separate from its receptor-sorting role. This dual identity expands the conceptual framework for how scaffolding proteins may control metabolic flux in vascular tissue. The mechanistic chain — GPRASP1 → ASNS stabilization → aspartate rerouting → TCA disruption → eNOS uncoupling → NO deficiency → vascular remodeling — is unusually complete for a single study and identifies ASNS as a potential druggable node. Key caveats apply: findings are currently confined to murine models, the translational relevance to human HFpEF patients requires validation in clinical cohorts, and metabolic interventions targeting ASNS carry systemic risks given asparagine's roles in protein synthesis. Still, this qualifies as a potentially paradigm-shifting mechanistic advance for a condition with conspicuously few therapeutic options.